**Table S1 Clinical characteristics of CRC patients in training phase**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **Age** | **Gender** | **Pathological diagnosis** | **TNM** | **Treatment** | **Weeks of treatment** |
| U1 | 54 | M | CRC | T2N1M0 | Naive | N/A |
| U2 | 36 | F | CRC | T3N1M0 | Naive | N/A |
| U3 | 72 | M | CRC | T4N0M0 | Naive | N/A |
| U4 | 31 | M | CRC | T2N1M0 | Naive | N/A |
| U5 | 47 | F | CRC | T1N0M0 | Naive | N/A |
| U6 | 48 | F | CRC | T4N1M0 | Naive | N/A |
| U7 | 51 | F | CRC | T3N0M0 | Naive | N/A |
| U8 | 44 | F | CRC | T3N1M1 | Naive | N/A |
| U9 | 47 | F | CRC | T3N1M0 | Naive | N/A |
| U10 | 49 | F | CRC | T2N0M0 | Naive | N/A |
| U11 | 52 | F | CRC | T2N1M0 | Naive | N/A |
| U12 | 59 | F | CRC | T3N1M1 | Naive | N/A |
| U13 | 63 | M | CRC | T2N2M0 | Naive | N/A |
| U14 | 51 | F | CRC | T3N1M0 | Naive | N/A |
| U15 | 42 | M | CRC | T3N2M0 | Naive | N/A |
| U16 | 47 | M | CRC | T2N0M0 | Naive | N/A |
| U17 | 36 | M | CRC | T3N1M0 | Naive | N/A |
| U18 | 39 | F | CRC | T2N1M0 | Naive | N/A |
| N1 | 58 | M | CRC | T3N1M0 | Oxaliplatin | 21 |
| N2 | 63 | M | CRC | T3N0M0 | Oxaliplatin | 21 |
| N3 | 39 | F | CRC | T4N2M0 | Oxaliplatin | 24 |
| N4 | 49 | M | CRC | T3N1M0 | Oxaliplatin | 21 |
| N5 | 72 | M | CRC | T3N2M1 | Oxaliplatin | 15 |
| N6 | 56 | M | CRC | T3N0M0 | Oxaliplatin | 21 |
| N7 | 43 | F | CRC | T3N0M0 | Oxaliplatin | 18 |
| N8 | 71 | M | CRC | T4N0M0 | Oxaliplatin | 11 |
| N9 | 40 | F | CRC | T3N1M0 | Oxaliplatin | 21 |
| N10 | 34 | F | CRC | T3N0M1 | Oxaliplatin | 21 |
| N11 | 67 | F | CRC | T3N1M1 | Oxaliplatin | 24 |
| N12 | 58 | M | CRC | T3N0M0 | Oxaliplatin | 21 |
| N13 | 63 | M | CRC | T2N0M0 | Oxaliplatin | 24 |
| N14 | 46 | M | CRC | T1N1M0 | Oxaliplatin | 18 |
| N15 | 39 | F | CRC | T4N0M0 | Oxaliplatin | 21 |
| N16 | 58 | M | CRC | T4N1M1 | Oxaliplatin | 21 |
| N17 | 57 | M | CRC | T2N2M0 | Oxaliplatin | 15 |
| N18 | 47 | M | CRC | T2N1M0 | Oxaliplatin | 21 |
| P1 | 45 | F | CRC | T3N0M0 | Oxaliplatin | 21 |
| P2 | 28 | F | CRC | T2N0M1 | Oxaliplatin | 15 |
| P3 | 37 | M | CRC | T3N1M0 | Oxaliplatin | 17 |
| P4 | 46 | F | CRC | T3N0M0 | Oxaliplatin | 21 |
| P5 | 57 | F | CRC | T4N0M0 | Oxaliplatin | 16 |
| P6 | 55 | M | CRC | T3N1M0 | Oxaliplatin | 21 |
| P7 | 37 | F | CRC | T4N2M1 | Oxaliplatin | 21 |
| P8 | 49 | M | CRC | T3N0M0 | Oxaliplatin | 21 |
| P9 | 51 | M | CRC | T2N2M0 | Oxaliplatin | 27 |
| P10 | 47 | F | CRC | T4N2M1 | Oxaliplatin | 21 |
| P11 | 68 | M | CRC | T3N1M0 | Oxaliplatin | 24 |
| P12 | 61 | F | CRC | T2N1M1 | Oxaliplatin | 24 |
| P13 | 59 | M | CRC | T3N2M0 | Oxaliplatin | 21 |
| P14 | 55 | M | CRC | T2N1M0 | Oxaliplatin | 24 |
| P15 | 50 | M | CRC | T2N1M0 | Oxaliplatin | 21 |
| **U**, patient without drug treatment; **N**, patient with neoadjuvant treatment; **P**, patient with relapse. |